No headlines found.
Enovis Announces Third Quarter 2025 Results
Globe Newswire (Thu, 6-Nov 6:01 AM ET)
Globe Newswire (Fri, 24-Oct 4:11 PM ET)
Globe Newswire (Wed, 8-Oct 8:15 AM ET)
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Enovis trades on the NYSE stock market under the symbol ENOV.
As of January 2, 2026, ENOV stock price declined to $26.51 with 745,167 million shares trading.
ENOV has a beta of 1.61, meaning it tends to be more sensitive to market movements. ENOV has a correlation of 0.32 to the broad based SPY ETF.
ENOV has a market cap of $1.52 billion. This is considered a Small Cap stock.
Last quarter Enovis reported $549 million in Revenue and $.75 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.09.
In the last 3 years, ENOV traded as high as $66.71 and as low as $25.47.
The top ETF exchange traded funds that ENOV belongs to (by Net Assets): IJR, VTI, VB, IWM, VBR.
ENOV has underperformed the market in the last year with a price return of -39.6% while the SPY ETF gained +17.8%. ENOV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.6% and -3.1%, respectively, while the SPY returned +2.8% and +2.0%, respectively.
ENOV support price is $25.88 and resistance is $27.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENOV shares will trade within this expected range on the day.